Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection

International Journal of Circumpolar Health

Volumn 71, Issue 1, 2012, Pages

  Livingston, Stephen E ^a   Townshend Bulson, Lisa J ^a   Bruden, Dana L ^b   Mcmahon, Brian J ^a,b   Homan, Chriss E ^a   Gove, James E ^a   Deubner, Heike ^c   Bruce, Michael G ^b   Robinson, Renee F ^d   Gretch, David R ^c  

^a ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d SOUTHCENTRAL FOUNDATION   (United States)

Author keywords

Hepatitis c treatment; Hepatology clinics; Treatment eligibility

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

ADULT; AMERICAN INDIAN; ARTICLE; COHORT ANALYSIS; DRUG COMBINATION; ETHNOLOGY; FEMALE; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; RETROSPECTIVE STUDY; STATISTICS; UNITED STATES;

ADULT; ALASKA; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; ELIGIBILITY DETERMINATION; FEMALE; HEPATITIS C; HUMANS; INDIANS, NORTH AMERICAN; INTERFERONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84860316731     PISSN: 12399744     EISSN: 22423982     Source Type: Journal    
DOI: 10.3402/ijch.v71i0.18445     Document Type: Article

References (14)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C. Hepatology. 2004; 39:1147-71.
4. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002; 36(5 Suppl. 1):S3-S20.
5. McMahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, Homan C, et al. Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology. 2004;39: 325-32.
6. McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology. 2010;138:922-31.
7. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, Follett EA, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol. 1995;76 (Pt 5):1197-204.
8. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1: 431-5.
9. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2010;30:240-50.
10. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005;12:81-5.
11. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136: 288-92.
12. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, et al. Expanding access to hepatitis C virus treatment - Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2012;52:1124-33.
13. Jacobson IM, McHutchison JG, Dusheiko GM et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study [Abstract]. Boston: Annual meeting American Association for the Study of Liver Diseases; 2010. Abstract 211.
14. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364: 1195-206.